Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 11/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15647583 | 1.00 | NAMPT (0.54) | NAMPTCYP3A4CYP2C9CYP2C19POLB | |
| SCHEMBL15645336 | 0.78 | NAMPT (0.57) | NAMPTCYP3A4CYP2C9CYP2C19POLB | |
| SCHEMBL15647056 | 0.78 | NAMPT (0.58) | NAMPTCYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL15646478 | 0.77 | SLC1A3 (0.45) | CYP3A4CYP2C9CYP2C19POLBTACR1 | |
| SCHEMBL15681449 | 0.77 | SLC1A3 (0.45) | CYP3A4CYP2C9CYP2C19POLBTACR1 | |
| SCHEMBL15647080 | 0.77 | NAMPT (0.56) | NAMPTCYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL19465696 | 0.77 | TACR1 (0.54) | CYP3A4TACR1MAPTKMT2AMEN1 | |
| SCHEMBL15646494 | 0.76 | NAMPT (0.55) | NAMPTCYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL15646125 | 0.75 | NAMPT (0.55) | NAMPTCYP3A4CYP2C9CYP2C19POLB | |
| Hydrochloric Acid SCHEMBL21995166 | 0.75 | KMT2A (0.58) | CYP2C9CYP2C19POLBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140113898-A1 | BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20140113898-A1 | BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20140113898-A1 | BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (US) | 2014-04-24 | — | — | US | disclosed |
| WO-2012061926-A1 | BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113898-A1 | BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1S, KCNN4 | NAMPT 4652/4885CYP3A4 322/4885CYP2C9 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.